Prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer

We thank Dr. Tirelli, Dr. Carbone, Dr. Francia and Dr. Di Francia for the interest they have taken in our paper “Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial”, and appreciate their comments (1,2).